Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289899 | 0.82 | HRH1 (0.53) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL4283597 | 0.81 | RAB9A (0.47) | SMN1; SMN2RAB9ANPC1MAOAMAOB | |
| SCHEMBL6400020 | 0.81 | RAB9A (0.47) | SMN1; SMN2RAB9ACA12CA1CA2 | |
| SCHEMBL18160699 | 0.80 | CHRM2 (0.53) | SMN1; SMN2RAB9AMAOAMAOBPOLB | |
| SCHEMBL29728447 | 0.79 | RAB9A (0.54) | SMN1; SMN2RAB9ACA1CA2NPC1 | |
| SCHEMBL30940202 | 0.79 | HRH1 (0.50) | SMN1; SMN2RAB9ACA12CA1CA2 | |
| SCHEMBL9129826 | 0.79 | RAB9A (0.54) | SMN1; SMN2RAB9ACA1CA2NPC1 | |
| SCHEMBL7358602 | 0.79 | CA12 (0.50) | SMN1; SMN2RAB9ACA12CA1CA2 | |
| SCHEMBL6237462 | 0.79 | HRH1 (0.50) | SMN1; SMN2RAB9ACA12CA1CA2 | |
| SCHEMBL6988794 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9ANPC1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | claimed |
| EP-1778299-A4 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INT BV (NL) | 2009-08-26 | — | — | EP | claimed |
| EP-1778299-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-02 | — | — | EP | claimed |
| WO-2006096207-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2006-09-14 | — | — | WO | claimed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | claimed |
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| EP-1778299-A4 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INT BV (NL) | 2009-08-26 | — | — | EP | disclosed |
| EP-1778299-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006096207-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2006-09-14 | — | — | WO | disclosed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | LDHB, FPGS, MTHFD2 | SMN1; SMN2 2575/4885RAB9A 4047/4885CA12 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.